Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF, Schofield RS, Hamilton KK, Herbert Patterson J, Adams KF Jr, Hill JA, Aranda JM Jr, Johnson JA. Lobmeyer MT, et al. Among authors: beitelshees al. Pharmacogenet Genomics. 2007 Apr;17(4):277-82. doi: 10.1097/FPC.0b013e3280105245. Pharmacogenet Genomics. 2007. PMID: 17496726
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).
Beitelshees AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, Langaee TY, Shriver MD, Sadee W, Knot HJ, Pepine CJ, Johnson JA; INVEST Investigators. Beitelshees AL, et al. Pharmacogenet Genomics. 2007 Sep;17(9):719-29. doi: 10.1097/FPC.0b013e32810f2e3c. Pharmacogenet Genomics. 2007. PMID: 17700361 Free PMC article. Clinical Trial.
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).
Gerhard T, Gong Y, Beitelshees AL, Mao X, Lobmeyer MT, Cooper-DeHoff RM, Langaee TY, Schork NJ, Shriver MD, Pepine CJ, Johnson JA; INVEST Investigators. Gerhard T, et al. Among authors: beitelshees al. Am Heart J. 2008 Aug;156(2):397-404. doi: 10.1016/j.ahj.2008.03.007. Epub 2008 Jun 20. Am Heart J. 2008. PMID: 18657677 Free PMC article. Clinical Trial.
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.
Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM, Gums J, Curry RW, Gong Y, Beitelshees AL, Schwartz G, Turner ST. Johnson JA, et al. Among authors: beitelshees al. Am Heart J. 2009 Mar;157(3):442-9. doi: 10.1016/j.ahj.2008.11.018. Am Heart J. 2009. PMID: 19249413 Free PMC article. Clinical Trial.
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.
Johnson JA, Gong Y, Bailey KR, Cooper-DeHoff RM, Chapman AB, Turner ST, Schwartz GL, Campbell K, Schmidt S, Beitelshees AL, Boerwinkle E, Gums JG. Johnson JA, et al. Among authors: beitelshees al. Clin Pharmacol Ther. 2009 Nov;86(5):533-9. doi: 10.1038/clpt.2009.101. Epub 2009 Jul 1. Clin Pharmacol Ther. 2009. PMID: 19571804 Free PMC article. Clinical Trial.
160 results